Thus, uncovering other predictive biomarkers for immune blockade responses—such as CTLA-4/PD-1 expression on immune infiltrate and tumor cells, TILs, and circulating MDSCs and lymphocytes—should be prioritized in order to improve the efficacy of personalized treatments of patient (215, 216). This evidence concerns the gene PDCD1 and neoplasm.